Central	central	O	O	OTHERS	I
nervous	nervous	O	O	OTHERS	I
system	system	O	O	OTHERS	I
complications	complications	O	O	OTHERS	I
during	during	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
lymphoblastic	lymphoblastic	O	DISEASE	OTHERS	I
leukemia	leukemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
pediatric	pediatric	O	O	O	O
institution	institution	O	O	O	O
.	.	O	O	O	O

Central	central	O	O	OTHERS	I
nervous	nervous	O	O	OTHERS	I
system	system	O	O	OTHERS	I
(	(	O	O	OTHERS	I
CNS	cns	O	O	OTHERS	I
)	)	O	O	OTHERS	I
complications	complications	O	O	OTHERS	I
during	during	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
childhood	childhood	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
lymphoblastic	lymphoblastic	O	DISEASE	OTHERS	I
leukemia	leukemia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
ALL	all	O	O	O	O
)	)	O	O	O	O
remain	remain	O	O	O	O
a	a	O	O	O	O
challenging	challenging	O	O	O	O
clinical	clinical	O	O	O	O
problem	problem	O	O	O	O
.	.	O	O	O	O

Outcome	outcome	O	O	O	O
improvement	improvement	O	O	O	O
with	with	O	O	O	O
more	more	O	O	O	O
intensive	intensive	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
has	has	O	O	O	O
significantly	significantly	O	O	O	O
increased	increased	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
and	and	O	O	O	O
severity	severity	O	O	O	O
of	of	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
analyzed	analyzed	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
neurological	neurological	O	O	OTHERS	I
complications	complications	O	O	OTHERS	I
during	during	O	O	O	O
ALL	all	O	O	O	O
treatment	treatment	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
pediatric	pediatric	O	O	O	O
institution	institution	O	O	O	O
,	,	O	O	O	O
focusing	focusing	O	O	O	O
on	on	O	O	O	O
clinical	clinical	O	O	O	O
,	,	O	O	O	O
radiological	radiological	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
electrophysiological	electrophysiological	O	O	O	O
findings	findings	O	O	O	O
.	.	O	O	O	O

Exclusion	exclusion	O	O	O	O
criteria	criteria	O	O	O	O
included	included	O	O	O	O
CNS	cns	O	O	O	O
leukemic	leukemic	O	DISEASE	OTHERS	I
infiltration	infiltration	O	DISEASE	OTHERS	I
at	at	O	O	O	O
diagnosis	diagnosis	O	O	O	O
,	,	O	O	O	O
therapy-related	therapy-related	O	O	O	O
peripheral	peripheral	O	DISEASE	OTHERS	I
neuropathy	neuropathy	O	DISEASE	OTHERS	I
,	,	O	O	O	O
late-onset	late-onset	O	O	O	O
encephalopathy	encephalopathy	O	DISEASE	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
long-term	long-term	O	O	O	O
neurocognitive	neurocognitive	O	O	OTHERS	I
defects	defects	O	O	OTHERS	I
.	.	O	O	O	O

During	during	O	O	O	O
a	a	O	O	O	O
9-year	9-year	O	O	O	O
period	period	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
retrospectively	retrospectively	O	O	O	O
collected	collected	O	O	O	O
27	27	O	O	O	O
neurological	neurological	O	O	O	O
events	events	O	O	O	O
(	(	O	O	O	O
11	11	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
as	as	O	O	O	O
many	many	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
from	from	O	O	O	O
253	253	O	O	O	O
children	children	O	O	O	O
enrolled	enrolled	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
ALL	all	O	O	O	O
front-line	front-line	O	O	O	O
protocol	protocol	O	O	O	O
.	.	O	O	O	O

CNS	cns	O	O	O	O
complications	complications	O	O	O	O
included	included	O	O	O	O
posterior	posterior	O	O	O	O
reversible	reversible	O	O	O	O
leukoencephalopathy	leukoencephalopathy	O	DISEASE	OTHERS	I
syndrome	syndrome	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
10	10	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
stroke	stroke	O	DISEASE	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
5	5	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
temporal	temporal	O	DISEASE	OTHERS	I
lobe	lobe	O	DISEASE	OTHERS	I
epilepsy	epilepsy	O	DISEASE	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
2	2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
high-dose	high-dose	O	O	O	O
methotrexate	methotrexate	CHEMICALS	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
2	2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
syndrome	syndrome	O	O	OTHERS	I
of	of	O	O	OTHERS	I
inappropriate	inappropriate	O	O	OTHERS	I
antidiuretic	antidiuretic	O	O	OTHERS	I
hormone	hormone	O	O	OTHERS	I
secretion	secretion	O	O	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
1	1	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
other	other	O	O	O	O
unclassified	unclassified	O	O	O	O
events	events	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
7	7	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
conclusion	conclusion	O	O	O	O
,	,	O	O	O	O
CNS	cns	O	O	O	O
complications	complications	O	O	O	O
are	are	O	O	O	O
frequent	frequent	O	O	O	O
events	events	O	O	O	O
during	during	O	O	O	O
ALL	all	O	O	O	O
therapy	therapy	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
require	require	O	O	O	O
rapid	rapid	O	O	O	O
detection	detection	O	O	O	O
and	and	O	O	O	O
prompt	prompt	O	O	O	O
treatment	treatment	O	O	O	O
to	to	O	O	O	O
limit	limit	O	O	O	O
permanent	permanent	O	O	O	O
damage	damage	O	O	O	O
.	.	O	O	O	O

